CCL2 and neoplasm: To address this critical question, we constructed LL2 subcutaneous tumour models of WT, CCL2−/−, and LTB4R−/− mice and treated them with oxPAPC on day 0 after tumour inoculation (10 mg/kg, intraperitoneal injection, once every other day).